Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
The advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
To accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
Use the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-HLA-A chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human HLA-A. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HLA-A antibody linked to 4-1BB(CD137), OX40 and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.
Specific Inquiry
Add to Cart
Details
Target
HLA-A
Targeting Cell Type
T cell
Targeting Diseases
Plasma membrane
Generation
Second
Vector Name
pCDCAR1
Vector Length
~8kb
Vector Type
Lentiviral vector
Receptor Construction
scFv-41BB-CD3ζ
Discription of Signaling Cassetes
41BB CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells and binds to a high-affinity ligand (4-1BB) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity. CD3ζ CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMS, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound.CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
Major Histocompatibility Complex, Class I, A; HLA Class I Histocompatibility Antigen, A-1 Alpha Chain; HLAA; HLA Class I Histocompatibility Antigen, A-10 Alpha Chain; HLA Class I Histocompatibility Antigen, A-28 Alpha Chain; HLA Class I Histocompatibility Antigen, A-9 Alpha Chain; MHC Class I Antigen HLA-A Heavy Chain; Leukocyte Antigen Class I-A; MHC Class I Antigen A*11; MHC Class I Antigen A*23; MHC Class I Antigen A*24; MHC Class I Antigen A*25; MHC Class I Antigen A*26; MHC Class I Antigen A*29; MHC Class I Antigen A*30; MHC Class I Antigen A*31; MHC Class I Antigen A*32; MHC Class I Antigen A*33; MHC Class I Antigen A*34; MHC Class I Antigen A*36; MHC Class I Antigen A*43;
Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
Customer Reviews and Q&As
There are currently no customer reviews or questions for Anti-HLA-A (CBFYH-1261) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-WFY6830). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.